The spin trap reagent PBN attenuates degeneration of 5-HT neurones in rat brain induced by p-chloroamphetamine but not fenfluramine

Neuropharmacology

Volumn 35, Issue 11, 1996, Pages 1615-1620

  Murray, T K ^a,c   Williams, J L ^a   Misra, A ^a   Colado, M I ^b   Green, A R ^a  

^a ASTRAZENECA   (United Kingdom)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c Astra Arcus   (United Kingdom)

Author keywords

Phenyl N tert butyl nitrone (PBN); 5 Hydroxytryptamine; 3H paroxetine binding; Fenflurane; Free radicals; Neurodegeneration; p Chloroamphetamine

Indexed keywords

1,4 BENZOQUINONE; 5 HYDROXYINDOLEACETIC ACID; CATECHOL; CHLORAMPHETAMINE; FENFLURAMINE; FREE RADICAL; N TERT BUTYL ALPHA PHENYLNITRONE; NEUROTOXIN; PAROXETINE; RADIOLIGAND; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; DRUG METABOLISM; DRUG RECEPTOR BINDING; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NERVE CELL DEGENERATION; NONHUMAN; PRIORITY JOURNAL; RAT; RECTUM TEMPERATURE; SEROTONIN BRAIN LEVEL; SEROTONINERGIC NERVE CELL;

ANIMALS; BODY TEMPERATURE; BRAIN; BRAIN CHEMISTRY; FENFLURAMINE; HYDROXYINDOLEACETIC ACID; MALE; NERVE DEGENERATION; NEURONS; NITROGEN OXIDES; P-CHLOROAMPHETAMINE; PAROXETINE; RATS; SEROTONIN; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS; SPIN LABELS; SPIN TRAPPING;

EID: 0030458376     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(96)00118-9     Document Type: Article

References (32)

1. Berger U. V., Gu X. F., Vandange J. W. L. and Azmitia E. C. (1992) Evidence for a common mechanism of serotonin release induced by substituted amphetamines in vitro. Ann. N.Y. Acad. Sci. 648: 358-360.
2. Broening H. W., Bowyer J. F. and Slikker W. J. (1995) Age-dependent sensitivity of rats to the long-term effects of the serotonergic neurotoxicant (±)-3,4-methylenedioxymethamphetamine (MDMA) correlates with the magnitude of the MDMA-induced thermal response. J. Pharmacol. Exp. Ther. 275: 325-333.
3. Busto R., Dietrich W. D., Globus M. Y., Valdes I., Steinberg P. and Ginsberg W. D. (1987) Small differences in intraischemic brain temperature cortically determine the extent of ischemic brain injury. J. Cereb. Blood Flow Metab. 7: 729-738.
4. Caccia S., Ballabio M., Guiso G., Rochetti M. and Garattini S. (1982) Species differences in the kinetics and metabolism of fenfluramine isomers. Ann. Int. Pharmacodyn. Ther. 258: 15-28.
5. Campbell D. B. (1971) Plasma concentration of fenfluramine and its metabolite, norfenfluramine, after a single and repeated oral administration. Br. J. Pharmacol. 43: 465P-466P.
6. Carney J. M. and Floyd R. A. (1991) Protection against oxidative damage to CNS by α-phenyl-tert-butylnitrone (PBN) and other spin trapping agents: a novel series of non-lipid free radical scavengers. J. Molec. Neurosci. 3: 47-57.
7. Chiueh C. C., Miyake H. and Peng M. (1993) Role of dopamine antoxidation, hydroxyl radical generation and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism. Adv. Neurol. 60: 251-258.
8. Colado M. I. and Green A. R. (1995) The spin trap reagent α-phenyl-N-tert-butyl nitrone prevents "ecstasy"-induced neurodegeneration of 5-hydroxytryptamine neurones. Eur. J. Pharmacol. 280: 343-346.
9. Colado M. I., Murray T. K. and Green A. R. (1993) 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chloramethiazole and dizocilpine. Br. J. Pharmacol. 108: 583-589.
10. Colado M. I., Williams J. L. and Green A. R. (1995) The hyperthermic and neurotoxic effects of "Ecstasy" (MDMA) and 3,4-methylenedioxyamphetamine (MDA) in the Dark Agouti (DA) rat, a model of the CYP2D6 poor metabolizer phenotype. Br. J. Pharmacol. 115: 1281-1289.
11. Colado M. I., O'Shea E., Granados R., Murray T. K., Williams J. L. and Green A. R. (1996) Effect of MDMA and fenfluramine on the generation of free radicals in the rat hippocampus. Abstract, 8th Biennial Meet. Int. Soc. Free Radical Research, Barcelona.
12. Farfel G. M. and Seiden L. S. (1995) Role of hypothermia in the mechanism of protection against serotonergic toxicity. II Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan. J. Pharmacol. Exp. Ther. 272: 868-875.
13. Fuller R. W., Perry K. W. and Molloy B. B. (1975) Reversible and irreversible phase of serotonin depletion by 4-chloroamphetamine. Eur. J. Pharmacol. 33: 119-124.
14. Green A. R., Cross A. J. and Goodwin G. W. (1995) Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology 119: 247-260.
15. Harvey J. A. and McMaster S. E. (1975) Fenfluramine: evidence for a neurotoxic action in midbrain and long term depletion of serotonin. Pharmacol. Commun. 1: 217-228.
16. Henderson M. G., Hemrick-Luecke S. and Fuller R. W. (1992) MK801 protects against amphetamine-induced striatal dopamine depletion in iprindole-treated rats, but not against brain serotonin depletion after p-chloroamphetamine administration. Ann. N.Y. Acad. Sci. 648: 286-288.
17. Hewitt K. E. and Green A. R. (1994) Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ("ecstasy"). Neuropharmacology 33: 1589-1595.
18. Hiramatsu M., Kumagai Y., Unger S. E. and Cho A. K. (1990) Metabolism of methylenedioxymethamphetamine: formation of dihydroxymethamphetamine and a quinone identified as its glutathione addict. J. Pharmacol. Exp. Ther. 254: 521-527.
19. Jerina D. M. and Daly J. W. (1974) Arene oxides: a new aspect of drug metabolism. Science (Washington) 185: 573-582.
20. Lowry O. H., Rosebrough N. J., Farr A. L. and Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265-275.
21. Miller K. J., Anderholm D. C. and Ames M. M. (1986) Metabolic activation of the serotonergic neurotoxin parachloroamphetamine to chemically reactive intermediates by hepatic and brain microsomal preparations. Biochem. Pharmacol. 35: 1737-1742.
22. Molliver M. E., Berger U. V., Mamounas L. A., Molliver D. L., O'Hearn E. and Wilson M. A. (1990) Neurotoxicity of MDMA and related compounds: anatomic studies. Ann. N.Y. Acad. Sci. 600: 640-661.
23. Murray T. K., Misra A., Williams J. L., Colado M. I. and Green A. R. (1996) Effects of the spin trap reagent PBN on degeneration of 5-HT neurones induced by p-chtoroamphetamine and fenfluramine administration. Br. J. Pharmacol. 118: 123P.
24. Neckers L. M., Bertilsson L. and Costa E. (1976) The action of fenfluramine and p-chloroamphetamine on serotonergic mechanisms: a comparative study in rat brain nuclei. Neurochem. Res. 1: 29-35.
25. Parli C. J. and Schmidt B. (1975) Metabolism of 4-chloroamphetamine to 3-chloro-4-hydroxyamphetamine in rats: evidence for an in vivo "NIH Shift" of chlorine. Res. Commun. Chem. Pathol. Pharmacol 10: 601-610.
26. Sabol K. E., Richards J. B. and Seiden L. S. (1992) The NMDA receptor antagonist MK801 does not protect against serotonin depletion caused by high doses of DL-fenfluramine. Brain Res. 582: 129-133.
27. Sanders-Bush E., Bushing J. A. and Sulser F. (1972) Long term effects of p-chloroamphetamine on tryptophan hydroxylase activity and on the levels of 5-hydroxytryptamine and 5-hydroxyiadole acetic acid in brain. Eur. J. Pharmacol. 20: 385-388.
28. Schmidt C. J. (1987) Neurotoxicity of the psychedelic amphetamine methylenedioxymethamphetamine. J. Pharmacol. Exp. Ther. 240: 1-7.
29. Schmidt C. J., Black C. K. and Taylor V. L. (1991) L-DOPA potentiation of the serotonergic deficits due to a single administration of 3,4-methylenedioxymethamphetamine, p-chloroamphetamine or methamphetamine to rats. Eur. J. Pharmacol. 203: 41-49.
30. Schmidt C. J. and Taylor V. L. (1987) Depression of rat brain typtophan hydroxylase following acute administration of methylenedioxymethamphetamine. Biochem. Pharmacol. 36: 4095-4102.
31. Sprague J. E. and Nichols D. E. (1995) The monoamine oxidase-B inhibitor L-deprenyl protects against 3,4-methylenedioxymethamphetamine-induced lipid peroxidation and long-term serotonergic deficits. J. Pharmacol. Exp. Ther. 273: 667-673.
32. Steranka L. R. and Rehind A. W. (1987) Effect of cysteine on the persistent depletion of brain monoamines by amphetamine, p-chloroamphetamine and MPTP. Eur. J. Pharmacol. 133: 191-197.